NASDAQ · ACHV
Healthcare · Biotechnology
$7.24
Up+$0.21 (+2.99%)
Updated Oct 8, 2026, 2:05 AM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ACHV
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
ACHV closed at $7.24 after 21 trading sessions, down 3.98% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $7.02 | $7.3499 | $6.96 | $7.24 | 1.04M |
| Oct 6, 2026 | $7.06 | $7.23 | $6.8901 | $7.03 | 1.06M |
| Oct 5, 2026 | $7.24 | $7.3394 | $6.83 | $7.01 | 1.7M |
| Oct 2, 2026 | $7.62 | $7.63 | $7.05 | $7.24 | 1.89M |
| Oct 1, 2026 | $7.89 | $8.04 | $7.515 | $7.53 | 1.15M |
| Sep 30, 2026 | $8.08 | $8.28 | $7.87 | $8.09 | 2.38M |
| Sep 29, 2026 | $7.75 | $7.755 | $7.47 | $7.69 | 1.03M |
| Sep 28, 2026 | $7.50 | $7.84 | $7.3454 | $7.75 | 1.3M |
| Sep 25, 2026 | $7.90 | $7.955 | $7.51 | $7.54 | 1.42M |
| Sep 24, 2026 | $7.79 | $8.14 | $7.62 | $7.83 | 1.14M |
| Sep 23, 2026 | $8.15 | $8.2012 | $7.76 | $7.83 | 1.33M |
| Sep 22, 2026 | $8.15 | $8.42 | $7.95 | $8.12 | 1.67M |
| Sep 21, 2026 | $8.025 | $8.07 | $7.82 | $8.05 | 1.01M |
| Sep 18, 2026 | $7.91 | $8.09 | $7.802 | $7.98 | 2.83M |
| Sep 17, 2026 | $7.59 | $8.11 | $7.59 | $7.91 | 1.87M |
| Sep 16, 2026 | $7.43 | $7.62 | $7.265 | $7.42 | 1.91M |
| Sep 15, 2026 | $7.22 | $7.33 | $7.018 | $7.32 | 1.39M |
| Sep 14, 2026 | $7.06 | $7.29 | $7.0199 | $7.23 | 1.43M |
| Sep 11, 2026 | $7.38 | $7.44 | $7.01 | $7.06 | 1.46M |
| Sep 10, 2026 | $7.48 | $7.56 | $7.21 | $7.28 | 2.48M |
| Sep 9, 2026 | $7.82 | $7.85 | $7.52 | $7.54 | 2.37M |
The latest Smart Investors Daily articles mentioning ACHV.
Company
Market Activity
Research & News
ACHV research
Company profile and research snapshot.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 30, 2026 | Stifel | Buy | — |
| Aug 13, 2026 | Morgan Stanley | Overweight | — |
| Jun 22, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 21, 2026 | Canaccord Genuity | Buy | — |
| Apr 16, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 30, 2026
Stifel analyst James Condulis initiates coverage on Achieve Life Sciences (NASDAQ:ACHV) with a Buy rating and announces Price Target of $18.
Yahoo · Sep 28, 2026
SEATTLE and VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that new data evaluating the efficacy of 52 weeks of cytisinicline treatment for cigarette smoking and e-cigarette cessation will be presented at CHEST 2026, held October 18-21 in Phoenix, Arizona. CHEST 2
SeekingAlpha · Sep 23, 2026
Achieve Life Sciences is rated a 'buy' as it nears a second NDA resubmission after resolving prior manufacturing issues. Click for this ACHV stock update.
SeekingAlpha · Sep 22, 2026
Achieve Life Sciences (ACHV) stock outlook: cytisinicline CRL tied to manufacturing compliance, cash runway to 2027, dilution risks & quit-smoking...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ACHV.
